Skip to content
Screener

Shattuck Labs, Inc. STTK Shares (Diluted)

Shares (Diluted) at other companies

Eli Lilly logo
Eli LillyLLY
893.7M-0.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
2.4B+0.9%
Amgen logo
AmgenAMGN
544M+0.6%
AbbVie logo
AbbVieABBV
1.8B0.0%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
142.7M+16.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
43.6M+303%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$694.34M+1,861%
Enterprise value$633.72M-5,344%
P/S694.3×+683×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
RevenueThree Months Ended June 30, 2026 / $Three Months Ended June 30, 2026 / —Three Months Ended June 30, 2025 / $Three Months Ended June 30, 2025 / —Six Months Ended June 30, 2026 / $Six Months Ended June 30, 2026 / —Six Months Ended June 30, 2025 / $Six Months Ended June 30, 2025 / —
Interest income1,0298041,8321,416
Other expense(26)(230)(52)(155)
Total other income1,0035741,7801,261
Net loss$$(15,152)$$(12,458)$$(29,919)$$(26,160)
Unrealized (loss) gain on investments(63)1(69)(1)
Comprehensive loss$$(15,215)$$(12,457)$$(29,988)$$(26,161)
Net loss per share – basic and diluted$$(0.12)$$(0.24)$$(0.25)$$(0.51)
Weighted-average shares outstanding – basic and diluted129,779,29751,002,247121,675,47150,984,031

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s shares (diluted)?
Shattuck Labs, Inc. (STTK) reported shares (diluted) of 129.8M in Q2 2026.
How has Shattuck Labs, Inc.'s shares (diluted) changed year-over-year?
Shattuck Labs, Inc.'s shares (diluted) increased by 154.5% year-over-year, from 51M to 129.8M.
What is the long-term trend for Shattuck Labs, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), Shattuck Labs, Inc.'s shares (diluted) has grown at a 9.8% compound annual growth rate (CAGR), from 167.9M to 243.7M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Shattuck Labs, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude